Vanguard Group Inc. Decreases Stake in OrthoPediatrics Corp. (NASDAQ:KIDS)

Vanguard Group Inc. reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 3.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 923,890 shares of the company's stock after selling 32,165 shares during the period. Vanguard Group Inc. owned approximately 3.81% of OrthoPediatrics worth $21,416,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of KIDS. R Squared Ltd bought a new stake in shares of OrthoPediatrics in the fourth quarter worth about $48,000. KLP Kapitalforvaltning AS purchased a new position in OrthoPediatrics during the 4th quarter valued at approximately $79,000. BNP Paribas Financial Markets increased its stake in OrthoPediatrics by 125.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock worth $94,000 after acquiring an additional 1,929 shares during the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of OrthoPediatrics during the 4th quarter worth approximately $171,000. Finally, HighTower Advisors LLC purchased a new stake in shares of OrthoPediatrics during the 4th quarter worth approximately $268,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

Insider Transactions at OrthoPediatrics

In other news, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $133,224.74. Following the transaction, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This trade represents a 3.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares of the company's stock, valued at approximately $7,934,193.30. The trade was a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,732 shares of company stock worth $589,978. Insiders own 31.80% of the company's stock.

OrthoPediatrics Trading Up 2.0 %

Shares of KIDS traded up $0.41 during midday trading on Friday, hitting $21.00. The stock had a trading volume of 103,576 shares, compared to its average volume of 198,697. The stock's 50 day moving average is $23.80 and its 200 day moving average is $24.53. The firm has a market cap of $510.03 million, a PE ratio of -17.07 and a beta of 1.17. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics Corp. has a 1 year low of $20.26 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The company had revenue of $52.67 million for the quarter, compared to analyst estimates of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same period in the prior year, the company posted ($0.23) EPS. As a group, analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on KIDS shares. Stifel Nicolaus reduced their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Lake Street Capital assumed coverage on shares of OrthoPediatrics in a report on Monday, April 7th. They issued a "buy" rating and a $37.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 price target on shares of OrthoPediatrics in a report on Wednesday, April 9th. Finally, Truist Financial reduced their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $37.00.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.